Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband ...

Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...

Sue Bell was one of the first patients to receive the Alzheimer's drug lecanemab in 2020 as part of the clinical trial. It didn't stop the disease.

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

The available drugs for Alzheimer’s could only temporarily ease some symptoms—not change anything about the underlying ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.

With early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...